October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
HHS brief examines factors affecting generic use and cost savings
January 25th 2011With several blockbusters going off patent, Secretary Kathleen Sebelius of the U.S. Department of Health and Human Services asked the office of the Assistant Secretary for Planning and Evaluation to ?examine barriers to and identify opportunities for increasing generic use.?
Study proves that even with increased drug costs, adherence will reduce overall health spending
January 25th 2011A new study conducted by CVS Caremark and published in Health Affairs, found that among patients who had increased drug costs but were adherent with their medications, a ?substantial medical savings as a result of reductions in hospitalization and emergency department use? was realized.
SAMHSA reports 10 years of trends in alcohol- and substance-abuse treatment
January 25th 2011The United States Department of Health and Human Services division of Substance Abuse and Mental Health Services Administration has released a study examining trends of admissions to U.S. substance abuse treatment facilities of people aged 12 years and over, during the period from 1998 to 2008.
FDA sends complete response letter to MannKind regarding new inhaler
January 21st 2011FDA has sent MannKind Corp. a complete response letter regarding the company?s New Drug Application for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with types 1 and 2 diabetes for the control of hyperglycemia.
Merck halts vorapaxar study over bleeding concerns in stroke victims
January 21st 2011Concern that its drug vorapaxar, in trial for its potential to prevent clots, actually increased the risk of bleeding in stroke victims has prompted Merck & Co. to halt a late-stage study of the drug, the Associated Press reported.
FDA OKs label update for etravirine
January 20th 2011FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.
Generic competition on the horizon as many pharmaceutical companies face patent expirations
January 20th 2011The impact of generic drugs ? which now account for more than 70% of all prescriptions dispensed in the United States ? will continue to increase as some of the world?s most-prescribed products lose their patent protection in 2011 and begin facing generic competition.
FDA: Severe liver injury associated with dronedarone use
January 18th 2011Severe liver injury, including 2 cases of acute liver failure leading to liver transplant in patients treated with the medication, has been associated with the use of dronedarone (Multaq), according to an FDA Drug Safety Communication announcement.
NCPA applauds BB&T Corporation for preserving employees' choice in filling maintenance prescriptions
January 18th 2011The National Community Pharmacists Association commended BB&T Corporation's recent decision to reemphasize and continue its employees' choice in filling their maintenance prescriptions, including at independent community pharmacies.
HIV oral pre-exposure prophylaxis trial shows promise
January 18th 2011The first trial to provide evidence that drugs used to treat HIV can also help to prevent HIV infection among men who have sex with men (when combined with other prevention strategies) was reported late November online in the New England Journal of Medicine.
Longer oral contraceptive regimens containing a progestogen show higher effectiveness
January 18th 2011Compared with conventional 21-day regimens, 24-day oral contraceptive regimens containing a progestogen with a long half-life show higher contraceptive effectiveness under routine medical conditions, according to research published in the January 2011 issue of Obstetrics & Gynecology.
Oncology buy-and-bill evolving
January 15th 2011Oncology treatment and benefits are changing. Buy-and-bill, the traditional methodology that had physicians buying chemotherapeutic products, treating in the office, and billing the payer, is going the way of surgery by barbers. But no one is quite sure what will replace the one-time standard of payment.
E-tracking is the right prescription for U.S. meth problems
January 15th 2011The states that are looking for ways to stop illegal sales of pseudoephedrine should be commended. But a prescription requirement for cold and allergy medications that customers rely on every day is bad public policy that will have an unnecessary impact on many patients.